LAMC2 is a potential prognostic biomarker for cholangiocarcinoma

doi:10.3892/ol.2023.14120

CNU IR > Offices > 456 > Item 310902800/34798

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34798

Title:	LAMC2 is a potential prognostic biomarker for cholangiocarcinoma
Authors:	Ong, Khaa Hoo Hsieh, Yao-Yu Lai, Hong-Yue Sun, Ding-Ping Chen, Tzu-Ju Huang, Steven Kuan-Hua Tian, Yu-Feng Chou, Chia-Lin Shiue, Yow-Ling Wu, Hung-Chang Chan, Ti-Chun Tsai, Hsin-Hwa Li, Chien-Feng Kuo, Yu-Hsuan
Contributors:	Chi Mei Med Ctr, Dept Surg, Div Gastroenterol & Gen Surg Chung Hwa Univ Med Technol, Dept Med Technol Natl Sun Yat Sen Univ, Inst Biomed Sci Taipei Med Univ, Shuang Ho Hosp, Div Hematol & Oncol Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med,Div Hematol & Oncol China Med Univ, Coll Med, Sch Med, Dept Pharmacol Chi Mei Med Ctr, Dept Clin Pathol, Div Urol Chi Mei Med Ctr, Dept Surg, Div Urol Chang Jung Christian Univ, Coll Hlth Sci, Dept Med Sci Ind Chi Mei Med Ctr, Dept Surg, Div Colon & Rectal Surg Natl Sun Yat Sen Univ, Inst Precis Med Chi Mei Med Ctr, Dept Internal Med, Div Hematol & Oncol Chia Nan Univ, Coll Pharm & Sci Chi Mei Med Ctr, Dept Med Res Natl Hlth Res Inst, Natl Inst Canc Res China Med Univ Hosp, Dept Lab Med Chi Mei Med Ctr, Trans Lab Precis Med
Keywords:	laminin subunit gamma 2 prognosis cholangiocarcinoma heparin binding
Date:	2023
Issue Date:	2024-12-25 11:03:40 (UTC+8)
Publisher:	SPANDIDOS PUBL LTD
Abstract:	Cholangiocarcinoma is a common malignancy with increasing incidence worldwide. Most patients are diagnosed at the advanced stage with poor survival rate. Laminin subunit gamma 2 (LAMC2) is a heparin binding-associated gene involved in tumorigenesis and has been implicated in the prognosis of various types of cancers. However, it is unclear whether expression of LAMC2 is associated with the clinical outcome of patients with cholangiocarcinoma. In the present study, the role and prognostic value of LAMC2 expression in patients with cholangiocarcinoma was investigated. Clinical information and pathological characteristics were analyzed and the association between LAMC2 expression and clinical characteristics, pathological findings and patient outcomes, including metastasis-free and disease-specific survival, were investigated. Data from 182 patients with cholangiocarcinoma were evaluated. High LAMC2 expression was associated with higher tumor stage (P<0.001), large duct type (P=0.024) and poor histological grade (P=0.002). Kaplan-Meier analysis showed high LAMC2 expression was associated with lower overall (P=0.003), disease-specific (P=0.0025), local recurrence-free (P<0.0001) and metastasis-free survival (P<0.0001). Moreover, multivariate analysis demonstrated that increased LAMC2 expression was a significant predictive risk factor for overall [hazard ratio (HR) 1.713; P=0.034], disease-specific (HR 2.011; P=0.039), local recurrence-free (HR 2.721; P<0.001) and metastasis-free survival (HR 3.117; P<0.001). Gene enrichment analysis using Gene Ontology showed that terms associated with LAMC2 upregulation were 'regulation of platelet-derived growth factor receptor-beta signaling pathway' and 'platelet-derived growth factor receptor-beta signaling pathway'. The present study indicated that LAMC2 was upregulated in cholangiocarcinoma tumor tissue and had an inverse association with overall, disease-specific, local recurrence-free and metastasis-free survival in patients with cholangiocarcinoma. These results suggested that LAMC2 may serve as a potential biomarker for cholangiocarcinoma.
Relation:	Oncology Letters, v.26, n.6, Article 533
Appears in Collections:	[Offices] 456

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1	View/Open

Loading...